XML 76 R66.htm IDEA: XBRL DOCUMENT
v3.23.3

Subsequent Events (Details) - USD ($) $ in Millions | Oct. 31, 2023 | Oct. 17, 2023 | Sep. 30, 2023 | Jul. 31, 2023 | Oct. 31, 2022 | Jun. 30, 2022
--- | --- | --- | --- | --- | --- | ---
Subsequent event | Term Loan C | Loan Agreement |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |
Additional committed capital |  | $ 50.0 |  |  |  |
Subsequent event | Term Loan D | Loan Agreement |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |
Additional uncommitted capital |  | 50.0 |  |  |  |
Subsequent event | Term Loan B | Loan Agreement |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |
Remaining funding based on milestone achievement |  | $ 22.5 |  |  |  |
KKC | Licensing revenue | 2017 KKC Agreement |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |
Proceeds from milestone payments |  |  | $ 30.0 |  | $ 35.0 |
Healthcare royalty partners IV, L.P | Licensing revenue |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |
Payment to be received |  |  | $ 5.0 |  |  | $ 5.0
Fosun Pharma | Fosun Agreement |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |
Proceeds from milestone payments |  |  |  | $ 2.0 |  |
Fosun Pharma | Fosun Agreement | Subsequent event |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |
Proceeds from milestone payments | $ 3.0 |  |  |  |  |

X
- Definition Line Of Credit Facility, Accordion Feature, Additional Committed Capital + References No definition available. + Details
Name: | ardx_LineOfCreditFacilityAccordionFeatureAdditionalCommittedCapital
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line Of Credit Facility, Accordion Feature, Additional Uncommitted Capital + References No definition available. + Details
Name: | ardx_LineOfCreditFacilityAccordionFeatureAdditionalUncommittedCapital
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Remaining Funding Based On Conditional Milestone Achievement + References No definition available. + Details
Name: | ardx_RemainingFundingBasedOnConditionalMilestoneAchievement
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount + References No definition available. + Details
Name: | ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ardx_TermLoan2022CMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ardx_TermLoan2022DMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |